Dainippon Sumitomo's antipsychotic lurasidone positive in second Phase III study
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma's once-daily atypical antipsychotic lurasidone has met the primary endpoint of the second of three trials, PEARL 2, in its pivotal Phase III programme for schizophrenia.